CM-272

CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC50s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death[1].

Product Specifications

CAS Number

[1846570-31-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; DNA Methyltransferase; Histone Methyltransferase

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cm-272.html

Concentration

10mM

Purity

98.70

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CN(CC1)CCC1NC2=CC(C3=CC=C(C)O3)=NC4=CC(OCCCN5CCCC5)=C(OC)C=C42

Molecular Formula

C28H38N4O3

Molecular Weight

478.63

Precautions

H302, H315, H319, H335

References & Citations

[1]San José-Enériz E, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017 May 26;8:15424.